MedTrace Logo

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

NCT02852486 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate treatment-free remission after imatinib discontinuation in patients with chronic myeloid leukemia with deep molecular response. Before discontinuation, patients will receive pioglitazone associated with imatinib during 3 months.

Conditions

  • Leukemia, Chronic Myeloid

Interventions

DRUG

Pioglitazone 30 Mg Oral Tablet

30 mg/day, orally, for 3 months, before imatinib discontinuation

OTHER

imatinib discontinuation

imatinib discontinuation after 3 months of pioglitazone

Sponsors & Collaborators

  • University of Campinas, Brazil

    lead OTHER

Principal Investigators

  • Katia B Pagnano, MD · University of Campinas

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2024-02-07
Completion
2024-02-07

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852486 on ClinicalTrials.gov